Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker and ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker and M...
Find Industry reports, Company profilesReportLinker and Mark...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
of 8

Nanotechnology: Players, products & prospects to 2018 (Volume II)

Nano-enabled DeliveryThe true value of nanotechnology lies in its potential to improve the solubility and enhance the efficiency of product delivery. It has been successfully applied to the commercialisation of more than 30 drugs. Regulators have published numerous white papers on the topic and established Task Forces to monitor the progress and application of this technology although there are presently no regulations specific to nanomedicine or nano-enabled medical devices.As the field of nanotechnology gains momentum and nano-enabled platforms emerge to address the industry's need for therapeutic, bioavailable and less toxic products, this market is expected to grow significantly over the next decade. Proof of concept data with novel compounds is accumulating and new formulations of old chemotherapeutic drugs offer the promise to revolutionise cancer therapies.The potential of future applications: Tissue specific delivery ' targeting the delivery of small and macro molecules across biological membranes such as the blood brain barrier for CNS drugs;Gene and vaccine delivery ' non-viral delivery of genetic materials in nanohydrogels and nanocarriers with a high degree of efficiency and expression;Controlled-release devices ' design of new nanoporous, bioerodible membranes;Increased biocompatibility ' design of artificial surfaces engineering for medical and dental implants to by-pass unwanted inflammatory response;Improved drug bioavailability and solubility ' through the engineering of drugs and reagents by nanostructuring;Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for the safe targeted delivery of toxic therapeutic drugs. By 2018, the market could exceed US$13 billionBy 2018 the established nanotechnology product market will be US$10.2 billion. The market will mature as the number of marketed nano-enabled products doubles and second generation nanomedicines begin to emerge. These agents will address areas of high unmet clinical need and result in the formulation of approved and novel drugs which are safer, less toxic and more efficacious than first generation products.By 2018 these second generation nanomedicines could generate sales of nearly US$2.9 billion and establish nanotechnology as an important tool in the industry's delivery armoury. A range of proprietary delivery platforms will utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles to target a number of therapy areas such as CNS disorders, oncology and infectious diseases.This report is part of a major new 4-volume strategic analysisDrug Delivery Technologies:Players, Products & Prospects to 2018Focusing on the sectors that are driving growthVOLUME ICONTROLLED- RELEASEVOLUME IINANOTECHNOLOGYVOLUME IIINUCLEIC ACID DELIVERYVOLUME IVTARGETED DELIVERYClick here for details of the full report >> CONTENTSEXECUTIVE SUMMARY & INTRODUCTION - Overview of nanotechnology: past, present & future - Nanotechnology: motivators & resistors - Nanomedicines, formulations and product regenerationNANOTECHNOLOGY IN DRUG DELIVERY - Core nanotechnology used by the pharma industry - Nano-engineered drugs - Nano-carriers: Dendrimer, liposome micelle and polymeric nanoparticle structures - Current therapeutic applications of nanotechnology in drug delivery - Leading brands that utilise nanotechnology delivery - Future commercial applications & opportunitiesSTRATEGIES OF DRUG DELIVERY COMPANIES - Leading nanotechnology drug delivery companies - Strategic development & commercialisation partnerships and joint ventures - Mergers, acquisitions, start-ups & spin offs - Intellectual propertyTHE CURRENT & FUTURE MARKET - Leading approved nano-enabled product sales 2009 - Companies developing nano-enabled product sales 2009 - Novel nano-enabled product sales 2018 - Global nano-enabled product sales 2018COMPETITOR ANALYSISDetailed analysis of leading companies covering: - Proprietary delivery technology - Applications in the pharma industry
Published on: Mar 3, 2016
Published in: Technology      Business      
Source: www.slideshare.net


Transcripts - Nanotechnology: Players, products & prospects to 2018 (Volume II)

  • 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Nanotechnology: Players, products & prospects to 2018 (Volume II)Published on June 2009 Report SummaryNano-enabled DeliveryThe true value of nanotechnology lies in its potential to improve the solubility and enhance the efficiency of product delivery. It hasbeen successfully applied to the commercialisation of more than 30 drugs. Regulators have published numerous white papers on thetopic and established Task Forces to monitor the progress and application of this technology although there are presently noregulations specific to nanomedicine or nano-enabled medical devices.As the field of nanotechnology gains momentum and nano-enabled platforms emerge to address the industrys need for therapeutic,bioavailable and less toxic products, this market is expected to grow significantly over the next decade. Proof of concept data withnovel compounds is accumulating and new formulations of old chemotherapeutic drugs offer the promise to revolutionise cancertherapies.The potential of future applications:Tissue specific delivery targeting the delivery of small and macro molecules across biological membranes such as the blood brainbarrier for CNS drugs;Gene and vaccine delivery non-viral delivery of genetic materials in nanohydrogels and nanocarriers with a high degree of efficiencyand expression;Controlled-release devices design of new nanoporous, bioerodible membranes;Increased biocompatibility design of artificial surfaces engineering for medical and dental implants to by-pass unwanted inflammatoryresponse;Improved drug bioavailability and solubility through the engineering of drugs and reagents by nanostructuring;Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for the safe targeted delivery of toxic therapeutic drugs.By 2018, the market could exceed US$13 billionBy 2018 the established nanotechnology product market will be US$10.2 billion. The market will mature as the number of marketednano-enabled products doubles and second generation nanomedicines begin to emerge. These agents will address areas of highunmet clinical need and result in the formulation of approved and novel drugs which are safer, less toxic and more efficacious thanfirst generation products.By 2018 these second generation nanomedicines could generate sales of nearly US$2.9 billion and establish nanotechnology as animportant tool in the industrys delivery armoury. A range of proprietary delivery platforms will utilise CaP technologies, FluidCrystals,micelles and polymeric nanoparticles to target a number of therapy areas such as CNS disorders, oncology and infectious diseases.This report is part of a major new 4-volume strategic analysisDrug Delivery Technologies:Players, Products & Prospects to 2018Focusing on the sectors that are driving growthNanotechnology: Players, products & prospects to 2018 (Volume II) Page 1/8
  • 2. Find Industry reports, Company profilesReportLinker and Market StatisticsVOLUME ICONTROLLED- RELEASEVOLUME IINANOTECHNOLOGYVOLUME IIINUCLEIC ACID DELIVERYVOLUME IVTARGETED DELIVERYClick here for details of the full report >>CONTENTSEXECUTIVE SUMMARY & INTRODUCTION- Overview of nanotechnology: past, present & future- Nanotechnology: motivators & resistors- Nanomedicines, formulations and product regenerationNANOTECHNOLOGY IN DRUG DELIVERY- Core nanotechnology used by the pharma industry- Nano-engineered drugs- Nano-carriers: Dendrimer, liposome micelle and polymeric nanoparticle structures- Current therapeutic applications of nanotechnology in drug delivery- Leading brands that utilise nanotechnology delivery- Future commercial applications & opportunitiesSTRATEGIES OF DRUG DELIVERY COMPANIES- Leading nanotechnology drug delivery companies- Strategic development & commercialisation partnerships and joint ventures- Mergers, acquisitions, start-ups & spin offs- Intellectual propertyTHE CURRENT & FUTURE MARKET- Leading approved nano-enabled product sales 2009- Companies developing nano-enabled product sales 2009- Novel nano-enabled product sales 2018- Global nano-enabled product sales 2018COMPETITOR ANALYSISDetailed analysis of leading companies covering:- Proprietary delivery technology- Applications in the pharma industry- Management/technical expertise- Competition within the delivery technology sector- Products in development/approved utilising the delivery technology- Sales forecasts of products using the delivery technology- Competitor ratio analysisCompanies analysed- Abraxis BioScience, Inc- Access Pharmaceuticals, Inc- AlphaRx Corporation- ALZA CorporationNanotechnology: Players, products & prospects to 2018 (Volume II) Page 2/8
  • 3. Find Industry reports, Company profilesReportLinker and Market Statistics- Aphios Corporation- Applied Pharma Research S.A.- BioSante Pharmaceuticals, Inc- Calando Pharmaceuticals, Inc- Camurus A.B.- Cerulean Pharma, Inc- CytImmune Sciences, Inc- Elan Corporation, Plc- Enzon Pharmaceuticals, Inc.- Gilead Sciences, Inc- Introgen Therapeutics- Mersana Therapeutics- Nano Interface Technology- Nano S Biotechnology GmbH- NanoBio Corporation- NanoBioMagnetics, Inc- Nanobiotix, Inc- NanoCarrier, Inc- Nanotechnology Victoria, Ltd.- NanoMaterials Technology- Nanotherapeutics, Inc- Novavax, Inc.- SkyePharma, Plc- Spherics Pharmaceuticals, Inc- Starpharma Holdings, LtdAPPENDICIES- Nanotechnology approved drug sales 2008-2018- Nanotechnology developmental drug sales 2008-2018- Key nanotechnology delivery companies by 2018Unique company & technology evaluationIt is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in awider competitive and market environment.In this report we present a précis on each of the leading delivery specialists and potential new delivery platforms and have identifiedtheir key attributes, based on a number of criteria including:Proprietary delivery technologyApplications of the delivery technology within the pharmaceutical industryManagement/technical expertise of the delivery specialistCompetition within the delivery technology sectorProducts in development/approved utilising the delivery technologyWe have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of upto 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom ranking table in each segment of themarket, dependent on their relative attributes.Multi-point evaluation and scoring assessmentPharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:Nanotechnology: Players, products & prospects to 2018 (Volume II) Page 3/8
  • 4. Find Industry reports, Company profilesReportLinker and Market StatisticsThe technologyComparison of delivery platforms within each area including: activated, degradation or diffusion for controlled-release systems;nano-engineered (nanocrystals, nanoparticle, nanosuspension) or nanocarriers (carbon/ceramic, dendrimer, liposome, micelle,polymeric nanoparticles) for nano-enabled delivery; viral or non-viral platforms for nucleic acid delivery and active or passive platformsfor targeted delivery systemsThe application of the technology within a number of therapy areasRoute of delivery (oral, parenteral, transdermal, implantable), delivery of small molecules/macromolecules and vaccines, additionalfeatures such as bioerodible materials etcThe current status of the technology in clinical development or following approvalNumber of approved and marketed products, clinical or preclinical development candidates, single or multiple products.Competition within the technology arenaAlternative drug delivery systems to technologies under evaluation, advantages and disadvantages over competitors.The drug delivery specialists expertiseNumber of drug delivery systems in development, strategic alliances, financial position, marketing presence.The product portfolioDrug delivery systems under evaluation, products in development, commercialisation/development partnerships.Potential drug salesBased on key events such as market, competition, patent expiry, time of entry into the market.About the AuthorDr Cheryl Barton is a highly regarded independent consultant with over 16 years research and business analysis experience.Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projectsranging from Alzheimers disease to schizophrenia. Dr Barton subsequently joined Dutch investment bank ABN Amro NV as a seniorequity analyst where she was lead analyst on major pharmaceutical companies such as Roche and Sanofi-Synthélabo, and assessedthe potential impact of new drug development on European Stocks.In 2002, Dr Barton founded a consulting business (www.Pharmavision.co.uk) to provide independent, tailor-made, pharmaceuticalthematic research to investment houses and pharmaceutical companies. The research reports combine independent scientificanalysis with patient-based models to forecast the potential sales growth of key drugs in clinical development. Table of ContentCONTENTSEXECUTIVE SUMMARY & INTRODUCTION- Overview of nanotechnology: past, present & future- Nanotechnology: motivators & resistors- Nanomedicines, formulations and product regenerationNANOTECHNOLOGY IN DRUG DELIVERY- Core nanotechnology used by the pharma industry- Nano-engineered drugs- Nano-carriers: Dendrimer, liposome micelle and polymeric nanoparticle structures- Current therapeutic applications of nanotechnology in drug delivery- Leading brands that utilise nanotechnology delivery- Future commercial applications & opportunitiesSTRATEGIES OF DRUG DELIVERY COMPANIESNanotechnology: Players, products & prospects to 2018 (Volume II) Page 4/8
  • 5. Find Industry reports, Company profilesReportLinker and Market Statistics- Leading nanotechnology drug delivery companies- Strategic development & commercialisation partnerships and joint ventures- Mergers, acquisitions, start-ups & spin offs- Intellectual propertyTHE CURRENT & FUTURE MARKET- Leading approved nano-enabled product sales 2009- Companies developing nano-enabled product sales 2009- Novel nano-enabled product sales 2018- Global nano-enabled product sales 2018COMPETITOR ANALYSISDetailed analysis of leading companies covering:- Proprietary delivery technology- Applications in the pharma industry- Management/technical expertise- Competition within the delivery technology sector- Products in development/approved utilising the delivery technology- Sales forecasts of products using the delivery technology- Competitor ratio analysisCompanies analysed- Abraxis BioScience, Inc- Access Pharmaceuticals, Inc- AlphaRx Corporation- ALZA Corporation- Aphios Corporation- Applied Pharma Research S.A.- BioSante Pharmaceuticals, Inc- Calando Pharmaceuticals, Inc- Camurus A.B.- Cerulean Pharma, Inc- CytImmune Sciences, Inc- Elan Corporation, Plc- Enzon Pharmaceuticals, Inc.- Gilead Sciences, Inc- Introgen Therapeutics- Mersana Therapeutics- Nano Interface Technology- Nano S Biotechnology GmbH- NanoBio Corporation- NanoBioMagnetics, Inc- Nanobiotix, Inc- NanoCarrier, Inc- Nanotechnology Victoria, Ltd.- NanoMaterials Technology- Nanotherapeutics, Inc- Novavax, Inc.- SkyePharma, Plc- Spherics Pharmaceuticals, Inc- Starpharma Holdings, LtdAPPENDICIES- Nanotechnology approved drug sales 2008-2018Nanotechnology: Players, products & prospects to 2018 (Volume II) Page 5/8
  • 6. Find Industry reports, Company profilesReportLinker and Market Statistics- Nanotechnology developmental drug sales 2008-2018- Key nanotechnology delivery companies by 2018Nanotechnology: Players, products & prospects to 2018 (Volume II) Page 6/8
  • 7. Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Nanotechnology: Players, products & prospects to 2018 (Volume II) Product Formats Please select the product formats and the quantity you require. 1 User License--USD 931.25 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Nanotechnology: Players, products & prospects to 2018 (Volume II) Page 7/8
  • 8. Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Nanotechnology: Players, products & prospects to 2018 (Volume II) Page 8/8

Related Documents